Fig. 2

High C3M/PRO-C3 ratio was predictive of treatment specific PFS in Stage 1 (discovery) and Stage 2 (validation) of HALO 109-202. In Stage 1 (discovery), C3M/PRO-C3 ratio subgroups were defined by a median cut-off and b ROC cut-off. In Stage 2 (validation), C3M/PRO-C3 ratio subgroups were defined by c median cut-off derived from Stage 1 and d ROC cut-off derived from Stage 1